Innovative Target Discovery Through T-cell Function Analysis

Boehringer Ingelheim, a leading German pharmaceutical company, has entered into a multi-year collaboration agreement with Immunai, an Israeli TechBio startup, for AI-driven target discovery. This collaboration focuses on elucidating the mechanisms of T-cell dysfunction, a key factor in cancer and autoimmune diseases, by leveraging Immunai's proprietary single-cell multi-omics data platform, 'AMICA-OS'. The companies will integrate data from these two previously distinct disease areas to explore novel T-cell targets for the development of first-in-class innovative drugs.

Streamlining Drug Development with Immune Data

Traditional drug screening methods have been limited by their time-consuming nature and high costs. Immunai's AMICA-OS analyzes clinical samples from thousands of patients and millions of immune cells to generate highly refined AI models that identify promising target genes. These selected targets will undergo functional perturbation and validation in Immunai's New York-based wet lab before being integrated into Boehringer Ingelheim's R&D pipeline, significantly reducing trial and error.

Global Big Pharma's Rush to Adopt Platforms

Through this partnership with Boehringer Ingelheim, Immunai has secured its third major contract with a global pharmaceutical company this year. It previously entered into a clinical-stage platform agreement with Bristol Myers Squibb in January 2026 and expanded its co-development of an anti-cancer drug with AstraZeneca in May, valued at $37.5 million. This demonstrates that traditional pharmaceutical companies are beginning to recognize and incorporate external, validated AI-driven precision immunology technologies as core infrastructure to improve new drug development success rates.

Emerging as a Game Changer in the Immunology Market

Currently, the global anti-cancer drug market and the autoimmune disease treatment market each represent a massive market of over $200 billion (USD), with significant unmet medical needs. T-cells play a central role in both of these diseases, and elucidating common mechanisms through single T-cell analysis is considered a groundbreaking innovation that could transform treatment paradigms. This agreement is expected to be a milestone in leading the new market in the immune therapy field, where AI technology is used in the early target discovery phase to address significant unmet needs.

Strategic Direction of the Medium- to Long-Term Partnership Extending to 2027

The two companies plan to maintain the contract until 2027 and jointly conduct initial target discovery projects, with an agreement to expand the collaboration if significant research results are achieved. Boehringer Ingelheim aims to fully integrate its immunology and oncology research capabilities with AI and machine learning technologies to enhance the development of next-generation therapeutics. The combination of a big pharma company that has declared a digital transformation and a strong TechBio company with a precision analysis platform will be an excellent template for open innovation in the future of new drug R&D.